@article{49105,
      url = {http://tind.wipo.int/record/49105},
      title = {Treating a Substance as an Active Ingredient.},
      abstract = {Regulation No. 469/2009 concerning the supplementary  protection certificate for medicinal products, Art. 1(b)  – Trastuzumab  Headnotes by the Editorial Office 1. The  assessment of the specific pharmacological, immunological  or metabolic action which is covered by the therapeutic  indications of a substance must be made with a view to the  contents of the marketing authorisation.  2. When the  marketing authorisation does not categorise a substance as  an ‘active ingredient’, there is a rebuttable  presumption that this substance has no pharmacological,  immunological or metabolic action of its own covered by the  therapeutic indications of this marketing authorisation.   Court of Cassation (Cour de cassation), judgment of 1  February 2023 – 101 FP-B on appeal D 21-15.221},
      doi = {https://doi.org/10.1093/grurint/ikad090},
      recid = {49105},
      pages = {1 online resource (pages 1074–1075)},
}